Disclosure of the use of FasL antagonists, e.g. of humanized antibodies directedagainst human Fas ligands (also named CD95L or Apo1L and hereinafter abbreviatedas FasL) for the prevention and/or treatment of skin diseases associated withkeratinocytes acantholysis, particularly for the prevention and/or treatmentof pemphigus.